Pharmakogenomik und Pharmakogenetik bei der arteriellen Hypertonie[¹]

Literatur

• 1 Barber B R, Ferrari P, Bianchi G. The Milan hypertensive strain: A description of the model. Elsevier Science in Ganten D, de Jong W (eds): Handbook of Hypertension: Experimental and Genetic Models of Hypertension 1994: 316-345
• 2 Barlassina C, Schork N J, Manunta P, Citterio L, Sciarrone M, Lanella G, Bianchi G, Cusi D. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion.  Kidney Int. 2000;  57 1083-1090
• 3 Bianchi G, Tripodi G, Casari G, Salardi S, Barber B R, Garcia R, Leoni P, Torielli L, Cusi D, Ferrandi M. Two point mutations within the adducin genes are involved in blood pressure variation.  Proc Natl Acad Sci U S A. 1994;  91 3999-4003
• 4 Carretero O A, Oparil S. Essential hypertension. Part I: definition and etiology.  Circulation. 2000;  101 329-335
• 5 Castellano M, Muiesan M L, Rizzoni D, Beschi M, Pasini G, Cinelli A, Salvetti M, Porteri E, Bettoni G, Kreutz R, Lindpaintner K, Rosei E A. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study.  Circulation. 1995;  91 2721-2724
• 6 Corvol P, Persu A AP, Jeunemaitre X. Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel.  Hypertension. 1999;  33 1324-1331
• 7 Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension [see comments] [published erratum appears in Lancet 1997; 350: 524.  Lancet. 1997;  349 1353-1357
• 8 Deutsche Liga zur Bekämpfung des hohen Blutdruckes - Deutsche Hypertonie Gesellschaft. Therapieempfehlungen .http://www.paritaet.org/rr-liga/indexv2.htm 2000
• 9 Dickerson J E, Hingorani A D, Ashby M J, Palmer C R, Brown M J. Optimisation of antihypertensive treatment by crossover rotation of four major classes.  Lancet. 1999;  353 2008-2013
• 10 Drazen J M, Yandava C N, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman E S, Katz D A, Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.  Nat Genet. 1999;  22 168-170
• 11 Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes.  J Hypertens. 1996;  14 259-262
• 12 Evans W E, Relling M V. Pharmacogenomics: translating functional genomics into rational therapeutics.  Science. 1999;  286 487-491
• 13 Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E, Melloni P, Bianchi G. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.  J Pharmacol Exp Ther. 1999;  288 1074-1083
• 14 Geller D S, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai F T, Sigler P B, Lifton R P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy [see comments].  Science. 2000;  289 119-123
• 15 Georgetown University Medical Center .Cytochrome P450 Drug Interaction Table. http://www.dml.georgetown.edu/depts/pharmacology/davetab.html 2000
• 16 Griffin J P. The withdrawal of mibefradil (Posicor) [editorial].  Adverse Drug React Toxicol Rev. 1998;  17 59-60
• 17 Hamet P, Pausova Z, Adarichev V, Adaricheva K, Tremblay J. Hypertension: genes and environment.  J.Hypertension. 1998;  16 397-418
• 18 Hofstra A H. Metabolism of hydralazine: relevance to drug-induced lupus.  Drug Metab Rev. 1994;  26 485-505
• 19 Hunt S C, Geleijnse J M, Wu L L, Witteman J C, Williams R R, Grobbee D E. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene.  Am J Hypertens. 1999;  12 460-466
• 20 Hübner N, Lee Y A, Lindpaintner K, Ganten D, Kreutz R. Congenic substitution mapping excludes Sa as a candidate gene locus for a blood pressure quantitative trait locus on rat chromosome 1.  Hypertension. 1999;  34 643-648
• 21 INSERM .Gene Canvas. http://genecanvas.idf.inserm.fr/
• 22 JNC VI . The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [published erratum appears in Arch Intern Med 1998 Mar 23; 158(6): 573] [see comments].  Arch Intern Med. 1997;  157 2413-2446
• 23 Jones J K, Gorkin L, Lian J F, Staffa J A, Fletcher A P. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population.  BMJ. 1995;  311 293-295
• 24 Kreutz R. Bedeutung der molekularen Diagnostik in der Kardiologie. in Blum HE, Siegenthaler W (Hrsg.): Molekularbiologie in der Inneren Medizin Georg Thieme Verlag, Stuttgart, New York 1997: 119-126
• 25 Kreutz R, Hübner N, Ganten D, Lindpaintner K. Genetic linkage of the ACE gene to plasma ACE acitivity, but not to blood pressure: a quantitative trait locus confers identical complex phenotypes in human and rat hypertension.  Circulation. 1995;  92 2381-2384
• 26 Kreutz R, Paul M, Ganten D. Hypertonie. in Gerok W, Huber C, Meinertz T, Zeidler H (Hrsg.): Die Innere Medizin Schattauer, Stuttgart 2000: 377-399
• 27 Kreutz R, Rothermund L, Dieterich M, Yagil Y, Yagil C, Paul M. Pharmacogenetic evaluation of the endothelin system reveals a secondary protective effect of ETA antagonism in the sabra rat model of salt-sensitive hypertension (Abstract).  Naunyn-Schmiedebergs Arch Pharmacol. 2000;  361 128 ((Suppl))
• 28 Kunz R, Beige J, Kreutz R, Distler A, Sharma A M. Association between the M235T allele and essential hypertension in caucasians. A systematic review and methodological appraisal.  Hypertension. 1997;  30 1331-1337
• 29 Lifton R P. Molecular genetics of human blood pressure variation.  Science. 1996;  272 676-680
• 30 Lindpaintner K, Pfeffer M A, Kreutz R, Stampfer M J, Grodstein F, LaMotte F, Buring J, Hennekens C H. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.  N Engl J Med. 1995;  332 706-711
• 31 Luft F C. Molecular genetics of human hypertension.  J Hypertens. 1998;  16 1871-1878
• 32 Manunta P, Burnier M, DAmico M, Buzzi L, Maillard M, Barlassina C, Lanella G, Cusi D, Bianchi G. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension.  Hypertension. 1999;  33 694-697
• 33 Manunta P, Cusi D, Barlassina C, Righetti M, Lanzani C, DAmico M, Buzzi L, Citterio L, Stella P, Rivera R, Bianchi G. Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients.  Kidney Int. 1998;  53 1471-1478
• 34 Mullins M E, Horowitz B Z, Linden D H, Smith G W, Norton R L, Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers.  JAMA. 1998;  280 157-158
• 35 Navis G, van der Kleij F G, de Zeeuw D, de Jong P E. Angiotensin-converting enzyme gene I/D polymorphism and renal disease.  J Mol Med. 1999;  77 781-791
• 36 Roses A D. Pharmacogenetics and the practice of medicine.  Nature. 2000;  405 857-65
• 37 Rubin E M, Tall A. Perspectives for vascular genomics [In Process Citation].  Nature. 2000;  407 265-269
• 38 Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences [see comments].  Am J Hum Genet. 1997;  60 284-295
• 39 Salardi S, Saccardo B, Borsani G, Modica R, Ferrandi M, Tripodi M G, Soria M, Ferrari P, Baralle F E, Sidoli A. Erythrocyte adducin differential properties in the normotensive and hypertensive rats of the Milan strain. Characterization of spleen adducin m-RNA.  Am J Hypertens. 1989;  2 229-237
• 40 Schulz A, Litfin A, Kovacevic L, Paul M, Kreutz R. Cosegregation analysis in a rat model with genetic hypertension and albuminuria (Abstract).  Hypertension. 2000;  36 668
• 41 Singer D R, Missouris C G, Jeffery S. Angiotensin-converting enzyme gene polymorphism - What to do about all the confusion?.  Circulation. 1996;  94 236-239
• 42 Stoll M AE, Cowley A WJ, Harris E L, Harrap S B, Krieger J E, Printz M P, Provoost A P, Sassard J, Jacob H J. New target regions for human hypertension via comparative genomics.  Genome Res. 2000;  10 473-482
• 43 Tripodi G, Valtorta F, Torielli L, Chieregatti E, Salardi S, Trusolino L, Menegon A, Ferrari P, Marchisio P C, Bianchi G. Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport [see comments].  J Clin Invest. 1996;  97 2815-2822
• 44 van Rossum C T, MH, Witteman J C, Hofman A, Mackenbach J P, Grobbee D E. Prevalence, treatment, and control of hypertension by sociodemographic factors among the Dutch elderly.  Hypertension. 2000;  35 814-821
• 45 Weir M R, Dworkin L D. Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy?.  Am J Kidney Dis. 1998;  32 1-22

Fußnote

1 Herrn Prof. Dr. med. Arnim Distler (ehem. Direktor der Medizinischen Klinik IV Endokrinologie und Nephrologie am Universitätsklinikum Benjamin Franklin der Freien Universität Berlin) anlässlich seines 65. Geburtstages und seiner Emeritierung in diesem Jahr gewidmet.

Korrespondenz